# A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients

> **NCT06418659** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** CD-801

## Key facts

- **NCT ID:** NCT06418659
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-12
- **Primary completion:** 2026-04
- **Final completion:** 2026-12
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06418659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06418659, "A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06418659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*